AlgoTherapeutix Receives Regulatory Approval to Initiate Clinical Development of ATX01
The Pharma Data
DECEMBER 14, 2020
AlgoTherapeutix recently raised a 12M€ Series A that will fund the Phase 1 and 2 clinical development of ATX01. In parallel, AlgoTx firmed-up ATX01’s development pathway via a pre-IND consultation with the FDA and obtained an Orphan Drug Designation from the FDA to explore ATX01’s activity in erythromelalgia.
52 
Let's personalize your content